Bioymifi is a small molecule that acts as a tumor necrosis factor-related apoptosis-induced ligand (TRAIL) mimetic. Upon binding to the death receptor 5 (DR5) on cancer cells, bioymifi triggers apoptosis,... Bioymifi is currently being investigated as an anti-tumor agent.
- Mechanism
- Curator reviewed · 3 references
In cancer cells, tumor necrosis factor (TNF)-related apoptosis-induced ligand (TRAIL) initiates apoptosis by binding to death receptor 5 (DR5). In contrast, normal cells express high levels of decoy receptors (DcRs) that partially or completely lack the functional death domain (DD). Therefore, the binding of TRAIL on normal cells does not induce cell death. Because of this, small molecules that mimic the activity of TRAIL may have the potential to act as chemotherapeutic agents. Bioymifi mimics the activity of TRAIL, and upon binding to the extracellular domain (ECD) of DR5, it induces clustering and aggregation in cancer cells, leading to apoptosis.
- Formula / weight
- C22H12BrN3O4S · 494.32 g/mol (avg)
Resolves to
ULBOWKXOFOTCMU-CPEDPXAASA-NSMILES[H]N=C1S\C(=C(\[H])C2=CC=C(O2)C2=CC3=C(C=C2)C(O)=NC3=O)C(=O)N1C1=CC=C(Br)C=C1What you can answer from here — as of April 02, 2025
Which drugs share a target with Bioymifi, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account